FNY Investment Advisers’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

FNY Investment Advisers’s Portfolio BCTXL Stock Details BCTXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,500	Closed	-$7K	–	1127
2026 Q1	$7K	Buy	+7,500	New	+$7.94K	﹤0.01%	583

FNY Investment Advisers's BCTXL Position: Q2 2026 in Review

FNY Investment Advisers sold out of BriaCell Therapeutics Warrant (BCTXL) in Q2 2026, closing a stake of 7,500 shares — an estimated $7K sold.

FNY Investment Advisers first reported a position in BCTXL in Q1 2026 and held it in 1 quarter. The position peaked at $7K in Q1 2026. 0 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.

FNY Investment Advisers reported no remaining BriaCell Therapeutics Warrant position as of Q2 2026 after selling out during the quarter.
FNY Investment Advisers sold 7,500 BriaCell Therapeutics Warrant shares in Q2 2026, an estimated $7K.
FNY Investment Advisers first reported a position in BriaCell Therapeutics Warrant in Q1 2026 and held it in 1 quarter.
FNY Investment Advisers's BriaCell Therapeutics Warrant position peaked at $7K in Q1 2026.
0 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.